Novo Nordisk loses GLP-1 drug lead to Eli Lilly
Danish pharmaceutical giant Novo Nordisk saw its dominance in GLP-1 weight-loss drugs challenged by U.S. rival Eli Lilly after pioneering breakthrough treatments.
En resumen
Novo Nordisk, once Europe’s most valuable company, has lost its lead in the GLP-1 weight-loss drug market to U.S. rival Eli Lilly. The shift follows Novo Nordisk’s struggle to sustain momentum after pioneering obesity treatments.
Novo Nordisk briefly surpassed LVMH to become Europe’s most valuable company by market capitalization in 2023.3 The company’s share price rose due to strong sales of its weight-loss drugs Ozempic and Wegovy.3 Novo Nordisk pioneered GLP-1 treatments for obesity, which drove its market value.3
After its initial success, Novo Nordisk has struggled to develop follow-up blockbuster drugs.3 U.S. rival Eli Lilly outmaneuvered Novo Nordisk in the weight-loss drug market.2 Eli Lilly took control of the diet-drug market from Novo Nordisk.2
Employers, including Bank of America, face rising costs due to demand for GLP-1 drugs like Ozempic and Wegovy.1 GLP-1 drugs can cost thousands of dollars per patient annually.1
Por qué importa
Este texto se escribió a partir de los 3 informes enumerados abajo, publicados por 3 medios independientes, y se cotejó con ellos línea por línea. No es una copia de ninguno. ¿Ves un error? Avísanos.
Discussion
0Comments are screened automatically. Disagreement is fine; abuse and spam are not.
Loading…
Related
News Øresund - Johan Wessman / CC BY 3.0Novo Nordisk shares fall as Wegovy pill sales miss forecasts
Novo Nordisk raised its full-year guidance for obesity and diabetes drugs but its US shares declined after the Wegovy weight-loss pill's sales did not meet analyst expectations.